The upregulated expression of thioredoxin domain-containing protein 5 (TXNDC5) is associated with rheumatoid arthritis in patients and model mice. However, the underlying mechanism by which TXNDC5 influences the pathological activation of rheumatoid arthritis synovial fibroblasts (RASFs) remains unknown. In this study, we show that TXNDC5 expression in RASFs and their cytokine production are significantly upregulated in response to LPS, TNF-α and IL-6, but suppressed by transfection with TXNDC5-siRNA. TXNDC5 is further validated as the direct target of NF-κB signaling. Mechanistically, TXNDC5 directly interacts with heat shock cognate 70 protein (HSC70) to sequester it in the cytoplasm, and HSC70 silencing exerts the same effects as TXNDC5 on the biological activity of RASFs (for example, decreased cell viability, invasion and cytokine production). Furthermore, HSC70 activates NF-κB signaling by destabilizing IκBβ protein in the absence of LPS or facilitating its nuclear translocation in the presence of LPS. Importantly, TXNDC5 can also regulate the activity of NF-κB signaling in a HSC70-IκBβ-dependent manner. Taken together, by linking HSC70 and NF-κB signaling, TXNDC5 plays a pro-inflammatory role in RASFs, highlighting a potential approach to treat RA by blocking the TXNDC5/HSC70 interaction.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by hyperplasia of synovial fibroblasts (SFs). 1 Rheumatoid arthritis synovial fibroblasts (RASFs) can express different molecules, such as toll-like receptors (TLRs), in response to the micro-environmental stimuli in the inflamed joints of RA patients. 2 Excessive inflammatory molecules, such as cytokines and matrix metalloproteinases, can be secreted and subsequently mediate the destruction of cartilage and bone. 3 The identification of components that are sensitive to the stimuli in the microenvironment of the inflamed joint is crucial to understand the pathogenesis of RA and may also provide new targets for diagnosis and treatment.
Thioredoxin domain-containing protein 5 (TXNDC5) is a protein-disulfide isomerase located in the endoplasmic reticulum that functions as a chaperone. 4 In a previous study, we found that TXNDC5 expression is significantly upregulated in the synovial tissues and fluids of RA patients. 5, 6 Using a gene silencing technique, our in vitro study demonstrated that TXNDC5 regulates biological activities, such as proliferation, invasion and cytokine production, in RASFs. 7 Importantly, our in vivo study showed that TXNDC5 overexpression in transgenic mice increases the susceptibility to and severity of collagen-induced arthritis. 7 Furthermore, we observed that nine SNPs in the gene encoding TXNDC5 are significantly associated with RA risk. 6 Recently, we also found that a microRNA, miR-573, plays an anti-inflammatory role in RA by suppressing TXNDC5 production in RASFs. 8 Thus, TXNDC5 deregulation is related to RA progression, and this protein warrants further study to elucidate its contributions to RA.
A previous study showed that TXNDC5 production increases in response to hypoxia, protecting endothelial cells against stress-induced cell death. 9 Our recent study demonstrated that the downregulation of TXNDC5 promotes prostate cancer progression, especially castration resistance, under an androgen-deprived condition. 10 These results demonstrate that TXNDC5 is needed to adapt to changes that may be harmful to cells. Our recent data further showed that TXNDC5 production is upregulated in RASFs following treatment with inflammatory mediators, such as LPS, IL-6 and TNF-α, indicating that TXNDC5 may act as a 'sensor' in RASFs to exacerbate inflammation; the mechanism underlying this function remains to be discovered. On the basis of these studies and interest in how TXNDC5 contributes to the activated phenotype of RASFs, we characterized the expression and pathogenic signaling pathway of TXNDC5 in RASFs under an inflammatory condition.
PATIENTS AND METHODS

Patients
Twelve patients with RA who had undergone knee joint replacement surgery were included without further selection. All of the RA patients fulfilled the 1987 American College of Rheumatology revised criteria for the diagnosis of RA. Written informed consent was obtained from every patient, and all samples were rendered anonymous.
Stimulation assays
Primary RASFs were isolated and cultured as described previously, 8 and the cells between passages 3-7 were used in the present study. For stimulation, RASFs were plated in 24-well plates (3-5 × 10 5 cells/well) in Dulbecco's Modified Eagle's Medium, and stimulated for the indicated time points with the following agents: lipopolysaccharide (LPS from Escherichia coli J5; Sigma, St Louis, MO, USA), TNF-α (Abnova, Taiwan, China), interleukin (IL)-6 (Abnova), VIPER (Novus Biologicals, Las Vegas, NV, USA), TAK242 (Millipore, Billerica, MA, USA) and cycloheximide (CHX, Sigma). The dilution buffer, PBS, was applied as a control for LPS or recombinant human TXNDC5. The activation of signaling pathways was blocked using BAY 11-7082, an NF-κB inhibitor, or PD98059, a selective MAP kinase kinase (MEK) inhibitor (all from Calbiochem/EMD Millipore, Billerica, MA, USA).
Small interfering RNA transfection in RASFs
RASFs (2 × 10 5 cells in 100-mm-diameter dishes or 8 × 10 4 cells in 6-well plates) were transiently transfected with siRNA targeting TXNDC5 (#1:SI00132440; #2: SI00132447, QIAGEN, Hilden, Germany) or negative control (QIAGEN, SI03650318) using Hiperfect transfection reagent (QIAGEN) following the manufacturer's instructions, and all experiments were performed 24-48 h after transfection. The specific siRNAs targeting TLR4 and HSC70 were designed and synthesized by RuiboBio, and the most effective single siRNA was used for further experiments as follows: siTLR4#1: CTACTACCTCG ATGATATT; siTLR4#2: GGAAACTTGGAAAAGTTTG; siHSC70#1: GTGCCATGACAAAGGATAA; siHSC70#2: GAACAAGAGAGCTGTAAGA; siIκBβ#1: GCGATGAATA CGACGACATTT; siIκBβ#2: CCGTTATCCACAAAGATC TTT. Non-specific negative control siRNAs were also designed and synthesized (sense strand: 5′-UUCUCCGAACGUG UCACG-3′ and anti-sense strand: 5′-ACGUGACACGU UCGGAGAATT-3′). Two siRNAs targeting the same gene above were mixed together in an equal volume to verify the reliability of the silencing efficiency and designated as siTXNDC5, siTLR4, siHEC70 or siIκBβ, respectively.
Cell viability
Briefly, 1 × 10 4 cells were seeded into each well of a 96-well plate for the indicated treatments. On the day of detection, 20 μl MTS (Promega, Carlsbad, CA, USA) was added to each well.
After incubation for 1 h at 37°C for 1 h, the plates were shaken at room temperature for 10 min. The absorbance was measured at 495 nm, and three independent experiments were analyzed.
Cell invasion assay
The cell invasion assay was performed using a transwell apparatus (Corning, Tewksbury, MA, USA). RASFs at a density of 3 × 10 4 cells/well were grown to confluence, and incubated with 100 nM of HSC70-specific siRNA in the upper compartment of the transwell apparatus for 48 h. After starvation, the medium in the lower compartment was replaced with DMEM supplemented with 10% FBS for another 24-h incubation at 37°C. After the removal of non-invading cells in the upper surface of the insert, the bottom surface of the insert was stained with Giemsa (Sigma). The number of cells that invaded through the membrane was quantified in five random fields at × 100 magnification.
ELISA
Cells were cultured and stimulated as described above, and supernatants were collected at the indicated time points. After centrifugation to remove particulates, the release of IL-8 and IL-6 (R&D Systems, Minneapolis, MD, USA) was analyzed by ELISA according to the manufacturer's instructions.
Western blot, GST pull-down and Co-immunoprecipitation (Co-IP) analysis Whole cell lysates were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidenedifluoride membrane (Amersham Biosciences, Little Chalfont, UK). Western blotting was performed using anti-TXNDC5 (1:1000, Sigma), anti-HSC70 (1:500, Abcam, Cambridge, MA, USA), phospho-p65 NF-κB (1:1000, Cell Signaling, Boston, MA, USA) or p65 NF-κB (1:1000, Cell Signaling). Lamin A (1:1000, Sigma) and glyceraldehyde-3-phosphate dehydrogenase (1:1000, GAPDH, Santa Cruz, Dallas, TX, USA) were applied as loading controls for nuclear and cytoplasmic proteins, respectively. GST pulldown was performed as described previously to evaluate the binding between exogenously expressed TXNDC5 and HSC70. 10 Immunoprecipitation was carried out to assess the interaction between endogenous levels of TXNDC5 and (Santa Cruz), the blots were detected using an ECL Plus detection system (Thermo Scientific, Pittsburgh, PA, USA).
RNA extraction and real-time RT-PCR (qRT-PCR)
RNA extraction and qRT-PCR was performed as previously described. 11 The details of the primers are depicted in Supplementary Table 1 . GAPDH was used as an internal loading control. Relative messenger RNA (mRNA) levels were measured using the 2-Δ cycle threshold (2-ΔCT) method. Three independent experiments were completed, and each reaction was performed in triplicate.
Chromatin immunoprecipitation and PCR assay (ChIP-PCR)
RASFs were untreated or treated with LPS for 24 h before the cells were fixed with 1% formaldehyde in medium for 10 min at room temperature. The shearing of nuclear lysates has been described in detail previously. 11 Chromatin was immunoprecipitated with IgG (Sigma) and anti-p65 (Abcam). The association of p65 was measured by RT-PCR (pre-denaturation at 95°C for 5 min, followed 95°C for 10 s, 60°C for 10 s and 72°C for 30 min, 40 cycles) in immunoprecipitated chromatin with the following primers: 5′-TGTGTGAGCTGAGAT-3′ (forward) and 5′-CGCTCTGCTCAGAGC -3′ (reverse). In the ChIP analysis with control primers against distinct promoter regions, no recruitment of p65 was observed. Input, chromatin input before immunoprecipitation; anti-p65, immunoprecipitated chromatin with anti-p65 antibody; IgG, immunoprecipitated chromatin with control IgG.
Luciferase reporter gene assay TLR4-transfected HeLa cells (2 × 10 4 cells/well; 96-well plate) were transfected with 80 ng/well luciferase reporter gene plasmid for NF-κB using Lipofectamine 2000, as described by the manufacturer (Invitrogen). pcDNA3.1-TXNDC5, pcDNA3.1-HSC70, TXNDC5-specific siRNA or HSC70-specific siRNA were transfected into the above cells as indicated. In all cases, 40 ng/well of phRL-TK reporter gene was co-transfected to normalize the data for the transfection efficiency. After 24 h, the cells were stimulated with LPS or TNF-α for 24 h. Cell lysates were prepared and reporter gene activity was measured using the Dual Luciferase Assay system (Promega) as previously described. 10 Data are expressed as the mean fold induction ± s.e.m. relative to control levels from a minimum of three separate experiments.
Statistical analyses
Statistical analysis of the data was performed using SPSS V.16 software (SPSS). The t test was used to assess significant differences between two groups. The correlation between TXNDC5 mRNA and HSC70 mRNA, TXNDC5 mRNA or TXNDC5 coordinates with HSC70 to exacerbate inflammation L Wang et al HSC70 mRNA and cytokine production in serum from RA patients was calculated by Spearman's correlation. P values o0.05 were considered significant. The data are presented as the s.d.
RESULTS
TXNDC5 is sensitive to extra-cellular stimuli and is required for the production of inflammatory factors in RASFs To understand the pathological mechanism of TXNDC5 in RA inflammation, we first investigated whether TXNDC5 expression is responsive to various inflammatory factors in RA. 12 Strikingly, IL-6 (I), TNF-α (II) and LPS (III) treatments could induce TXNDC5 expression in RASFs to varying degrees. Interestingly, the expression of TXNDC5 showed a dose ( Figure 1a ) and time-dependent (Figure 1b ) increase in response to the above-described stimulation. Our previous study showed that TXNDC5 could sensitize the activation of various signaling pathways to androgen or hypoxia, leading to a more aggressive phenotype of prostate cancer cells. 10 To further confirm whether TXNDC5 was related to the inflammatory phenotype of RASFs, we subjected RASFs to TXNDC5 knockdown. The silencing efficiency of two siRNAs specific to TXNDC5 was confirmed by Western blotting, and a combination of these two siRNAs at equal volume was designated as siTXNDC5 ( Figure 1c) . The results showed that, after stimulation with LPS (Figures 1d and e) and TNF-α (Figures 1f and g ), the increases in IL-6 and IL-8, which are key components exacerbating inflammation in RA, 12 were significantly attenuated at mRNA (I) and secreted protein (II) levels by silencing TXNDC5. These observations support that TXNDC5 may act as a mediator to promote inflammation in RA.
Activation of the NF-κB signaling pathway induces TXNDC5 expression under an inflammatory condition On the basis of above data, we found that LPS could induce TXNDC5 expression most dramatically ( Figure 1 ). As LPS is a known ligand for TLR4 and the TLR4-mediated signaling pathway is hyperactive in RA, [13] [14] [15] we reasoned that the increased expression of TXNDC5 following exposure to LPS might result from the activation of TLR4 signaling. As shown in Figures 2a and b , when TLR4 signaling was inhibited by treatment of RASFs with an siRNA specific for TLR4, antibody against TLR4, or a specific inhibitor targeting TLR4 (TAK-242), a modest reduction of TXNDC5 levels was observed. More importantly, the induction of TXNDC5 triggered by LPS stimulation in RASFs could be attenuated in the presence of treatments targeting TLR4 signaling. The silencing efficiency of siRNA targeting TLR4 was validated by western blotting (Figure 2c) . Moreover, signals from the various TLR4 ligands generally converge to the mitogen-activated protein kinases (MAPKs) or p65 nuclear-factor kappa B (p65 NF-κB). 14, 15 To further determine the mechanism accounting for the deregulated expression of TXNDC5 in RASFs, inhibitors targeting MAPK-ERK and NF-κB signaling were applied. Notably, inhibition of NF-κB signaling could most efficiently prevent the induction of TXNDC5 mRNA expression in response to LPS ( Figure 2d) ; this effect of the NF-κB inhibitor was further confirmed by western blot analysis (Figure 2e, I ). Subsequently, ChIP analysis was conducted, and the results demonstrated that p65 bound to the promoter of the gene encoding TXNDC5 (−360~− 272 bp), and its enrichment was greater in the presence of LPS treatment (Figure 2f ). The NF-κB signaling pathway is important for RA inflammation and can be activated by various pro-inflammatory factors such as IL-6 and TNF-α. 16, 17 To further confirm the regulation of TXNDC5 by NF-κB signaling, we studied the effects of an NF-κB inhibitor on IL-6-or TNF-α-induced TXNDC5 expression. As expected, inhibition of NF-κB signaling could also attenuate the induction of TXNDC5 in response to IL-6 (Figure 2e, II) or TNF-α (Figure 2e, III) . Furthermore, more p65 could be recruited to the promoter of TXNDC5 in the presence of IL-6 (Figure 2f ) or TNF-α (Figure 2f ) stimulation. Taken together, these data suggest that the increase of TXNDC5 expression in RASFs is likely attributable to the hyper-activation of NF-κB signaling in the inflamed microenvironment, and similar to NF-κB, TXNDC5 acts as a point of convergence of multiple inflammatory stimuli involved in RA, although the exact mechanism requires validation.
HSC70 forms a complex with TXNDC5 and, alone, mimics the effects of TXNDC5 on the biological activity of RASFs We further investigated the molecular mechanism by which TXNDC5 functions in the pathological inflammation associated with RA. STRING software (http://www.string-db.org/) was first applied to explore HSC70, as a potential TXNDC5 binding partner. Then, to confirm their interaction, GST pulldown was conducted, and bacterially expressed hTXNDC5-GST was mixed with extracts from RASFs in vitro. HSC70 bound to the TXNDC5-GST fusion protein according to a western blot analysis using anti-HSC70 antibodies, but it did not bind to GST alone (Figure 3a ). To further demonstrate an interaction between the endogenous TXNDC5 and HSC70 proteins, we immunoprecipitated TXNDC5 from RASFs and found that the immunoprecipitate contained HSC70 (Figure 3b, upper) . The interaction between them was further substantiated by immunoprecipitated HSC70 (Figure 3b,  lower) . Notably, their interaction could be strengthened in the presence of IL-6, TNF-α or LPS treatment, indicating that their interaction was functional. The control (IgG) antibodies provided only a background signal (Figure 3b) .
As a molecular chaperone similar to TXNDC5, the heat shock cognate 70 protein (HSC70) facilitates protein folding and is involved in pathologies such as cancer as well as cardiovascular, neurological, and hepatic diseases. 18 In addition, HSC70 has been reported to be highly expressed in RA 19 and holds promise as a player in the pathogenesis of RA. However, its exact role remains to be defined. To confirm the effect of HSC70 on the biological activity of RASFs, two siRNAs that efficiently silence HSC70 were selected (Figure 3c) . A functional study demonstrated that silencing HSC70 in RASFs decreased cell viability (Figure 3d, I ) and invasive capacity TXNDC5 coordinates with HSC70 to exacerbate inflammation L Wang et al (Figure 3d, II) . Furthermore, the introduction of HSC70 siRNA into RASFs suppressed the expression (I) and secretion (II) of IL-6 (Figures 3e and f) and IL-8 (Figures 3g and h ) in response to LPS (Figures 3e and g ) and TNF-α (Figures 3f and h) . Collectively, these results indicate that HSC70, similar to TXNDC5, is related to the inflammatory phenotype of RASFs.
HSC70 activates NF-κB signaling through its dual effects on IκBβ HSC70 can promote nuclear translocation of NF-κB and thus facilitate its activity. 20 We confirmed this activity in RASFs. First, silencing of HSC70 in RASFs could more efficiently suppress the level of phosphorylated p65 in response to LPS and TNF-α than their vehicle controls (Figure 4a) . Second, reduction of p65 in the nuclear compartment was observed in LPS-stimulated RASFs and HeLa cells when HSC70 was silenced, compared with the siRNA control (Figure 4b) . Furthermore, the increase in c-MYC (I) and VEGF (II) expression caused by LPS (Figure 4c ) and TNF-α (Figure 4d ) stimulation could be mitigated in the presence of HSC70 knockdown. Finally, silencing of HSC70 significantly decreased the NF-κB luciferase activity stimulated by LPS (Figure 4e, I ) and TNF-α (Figure 4e , II) in TLR4-transfected HEK293T cells. These findings suggest that HSC70 plays an important role in maintaining the inflammatory phenotype of RASFs by activating NF-κB signaling.
NF-κB signaling can be inactivated by I-kappa-B proteins (IκBα or IκBβ) through trapping NF-κB in the cytoplasm. 21 Furthermore, the loss of IκBβ contributes to basal NF-kB activity in the absence of LPS. 22 As HSC70 is involved in the were measured by qRT-PCR and ELISA following HSC70 silencing in the presence LPS (10 μg/ml, e and g) or TNF-α (10 ng/ml, f and h) stimulation for 24 h. The results are the means ± s.e.m. of three independent experiments performed in triplicate.*Po0.05 versus NC in the presence of the indicated treatment.
TXNDC5 coordinates with HSC70 to exacerbate inflammation L Wang et al protein degradation of its targets without LPS stimulation, 18 we propose that HSC70 may regulate the basal level of NF-κB signaling by destabilizing IκBβ. Thus, HSC70-specific siRNAtransfected RASFs were pre-treated with the protein synthesis inhibitor, CHX, to analyze the effects of HSC70 on IκBβ protein expression. Consistent with our hypothesis, silencing of HSC70 resulted in a significant increase in the IκBβ protein half-life (Figure 4f ), but not IκBα, indicating that HSC70 may activate NF-κB signaling by preventing its IκBβ-induced degradation. However, this effect was not obvious in the presence of LPS stimulation (data not shown). More importantly, we found that silencing HSC70 inhibited the nuclear translocation of IκBβ in the presence of long-term stimulation with LPS (12 h), indicating that, once activated, HSC70 may protect NF-κB p65 by promoting nuclear translocation of IκBβ in RASFs (Figure 4g ). However, the mechanism underlying this phenomenon remains to be resolved. IκBβ exists in two phosphorylation states: a hyperphosphorylated state in Figure 4 The NF-κB signaling pathway is modulated by HSC70. (a) RASFs transfected with HSC70-specific siRNAs or negative control (siCtrl) were either untreated or treated with LPS (10 μg/ml, I) and TNF-α (10 ng/ml, II) for 24 h. Thereafter, the cell lysates were examined for phospho-p65 (p-p65) or total p65 (t-p65) protein levels. The results are representative of three independent experiments. TXNDC5 coordinates with HSC70 to exacerbate inflammation L Wang et al quiescent, unstimulated cells and a hypophosphorylated newly synthesized state in LPS-stimulated cells. 22, 23 Newly synthesized IκBβ in the hypophosphorylated form presides mainly in the nucleus. 22, 23 We found that, after LPS treatment for 4 h, the hypophosphorylated level of IκBβ in HSC70-siRNA transfected RASFs was suppressed compared with its control (Figure 4h) , further confirming the effect of HSC70 on the nuclear translocation of IκBβ in the presence of LPS stimulation.
TXNDC5 activates NF-κB signaling through HSC70
Onthe basis of the above data, we questioned whether TXNDC5 could regulate the activity of NF-κB signaling in TXNDC5 coordinates with HSC70 to exacerbate inflammation L Wang et al
RASFs. We first detected the expression of the NF-κB target genes c-MYC and VEGF. 24 Consistent with HSC70, silencing TXNDC5 could attenuate the increase in c-MYC and VEGF expression (Figures 5a and b ) in response to LPS (I) or TNF-α (II) treatment. Next, we evaluated the effect of TXNDC5 on the activity of NF-κB signaling. The data showed that TXNDC5 knockdown in RASFs could block the phosphorylation of NF-κB p65 in response to LPS (I, Figure 5c ) and TNF-α (II, Figure 5c ). Furthermore, western blot analysis confirmed that the knockdown of TXNDC5 suppressed the phosphorylation level of NF-κB p65 in both the cytoplasmic and nucleic compartments of RASFs and HeLa cells following LPS stimulation ( Figure 5d ). As the plasmid transfection efficiency was extremely low in RASFs, we further selected HEK293T cells and, as expected, the luciferase activity of NF-κB in response to LPS or TNF-α stimulation was significantly inhibited after silencing TXNDC5 in TLR4-transfected HEK293T cells (Figure 5e ). Importantly, in parallel with siHSC70 in the absence of LPS, the half-life of IκBβ protein was higher in the TXNDC5 siRNA group than its control, although to a lesser extent than HSC70 siRNA (Figure 5f ). In contrast, after LPS stimulation for 12 h, silencing of TXNDC5 could suppress the nuclear translocation of IκBβ (Figure 5g ). Moreover, the hypophosphorylated level of IκBβ could also be suppressed after silencing TXNDC5 in RASFs treated with LPS for 4 h (Figure 5h ). To determine whether HSC70 is critical for TXNDC5-mediated activation of NF-κB signaling, nuclear translocation of p65 was analyzed. The data showed that silencing HSC70 could inhibit the nuclear translocation of p65 induced by TXNDC5 overexpression in LPS-stimulated HeLa cells (Figure 5i ). In contrast, the introduction of HSC70 prevented the suppression of p65 nuclear translocation in siTXNDC5-transfected HeLa cells (Figure 5j ). In addition, although forced expression of TXNDC5 upregulated NF-κB luciferase activity in the presence of LPS (I) or TNF-α (II), silencing of HSC70 led to a concomitant reduction (Figure 5k ). In contrast, overexpression of HSC70 blocked the reduction of luciferase activity caused by TXNDC5 suppression (Figure 5l) . To analyze the mediation mechanism of IκBβ towards TXNDC5/HSC70 on NF-κB, siRNA further enchanced IκBβ was utilized in HSC70-or TXNDC5-knockdown HeLa cells in the absence of LPS. The reduction of NF-κB signaling activity caused by HSC70 or TXNDC5 knockdown was inhibited by silencing IκBβ (Figure 5m ). In contrast, in the presence of LPS, introduction of IκBβ siRNA further enchanced the increase in NF-κB activity caused by HSC70 or TXNDC5 overexpression in HeLa cells (Figure 5n) . The silencing efficiency of siRNA targeting of IκBβ was validated by western blotting (Figure 5o ). These experiments provide evidence that TXNDC5 promotes inflammation in RASFs by potentiating the effects of HSC70/IκBβ-mediated NF-κB signaling.
TXNDC5 is related to HSC70 in RASFs HSC70 shuttles from the cytoplasm to the nucleus, and nuclear HSC70 relocates to the cytoplasm in a stress-dependent manner. 25 Our data showed that silencing TXNDC5 in RASFs could inhibit the nucleo-cytoplasmic shuttling of HSC70 and sequester HSC70 in nuclei (Figure 6a ), indicating that TXNDC5 facilitates the activity of HSC70 in the cytoplasm. In turn, the induction of TXNDC5 expression with respect to both RNA (Figure 6b ) and protein levels (Figure 6c) caused by IL-6 (I), TNF-α (II) or LPS (III) was attenuated when HSC70 was silenced in RASFs, suggesting the involvement of HSC70 in the pathological activity of TXNDC5 in RASFs. More To further support the inter-relationship between TXNDC5 and HSC70, the mRNA levels in RASFs were analyzed by RT-qPCR. A significant correlation was found between TXNDC5 and HSC70 levels (r 2 = 0.634, P = 0.027, Figure 6e) . Next, the correlation between TXNDC5 or HSC70 and inflammatory factors, such as TNF-α and IL-6, was determined. The expression levels of TXNDC5 (r 2 = 0.648, P = 0.023, Figure 6f ) and HSC70 (r 2 = 0.577, P = 0.049, Figure 6g ) were positively correlated with IL-6. Furthermore, a positive correlation was identified between TXNDC5 and TNF-α (r 2 = 0.73, P = 0.007, Figure 6h ), supporting the proinflammatory roles of TXNDC5 and HSC70 in RA. However, no significant correlation was found between HSC70 and TNF-α (r 2 = 0.419, P = 175, not shown).
DISCUSSION
RASFs play a central role in RA pathogenesis, as their hyperproliferation and excessive production of inflammatory factors lead to joint damage. 26 Our previous studies demonstrated that TXNDC5 is associated with the pathological progression of RA and can exacerbate the inflammatory phenotype of RASFs, TXNDC5 coordinates with HSC70 to exacerbate inflammation L Wang et al such as proliferation, invasion and cytokine production, as evidenced by both in vivo and in vitro experiments. 6, 7 Notably, TXNDC5 expression in RASFs could be induced in response to various stimuli, such as hypoxia and TLR4 agonist LPS, supporting its potential involvement in the immune response of RASFs that encounter inflammatory factors. 7, 8 In this study, we further establish that pro-inflammatory factors, namely, IL-6, TNF-α and LPS, drive the expression of TXNDC5, which suggests that TXNDC5 is sensitive to extracellular stimuli. RASFs, in turn, may require a higher level of TXNDC5 to adapt to the inflammatory condition residing in RA joints. In addition, we have previously found that overexpression of TXNDC5 sensitizes prostate cancer cells to hypoxia or androgen stimulation. 10 Consistent with this finding, our data showed that silencing TXNDC5 in RASFs suppressed LPSand TNF-α-induced production of cytokines IL-6 and IL-8.
Altogether with the observation that TXNDC5 is modulated by overlapping inflammatory factors, this protein may act as an inflammatory mediator that sensitizes RASFs to extracellular stimuli. TLRs are expressed in RASFs and can be activated by various endogenous ligands present in the inflamed joints of RA patients. 26 This process is followed by induction of NF-κB signaling, which leads to excessive production of cytokines. NF-κB signaling is central to the process of inflammation in RA, and the identification of key factors involving NF-κB signaling would highlight the pathological mechanism of RA and provide valuable treatment targets, such as TNF-α. 27, 28 In the present study, we validated TXNDC5 as a direct target of TLR4/NF-κB in RASFs, further supporting TXNDC5 as a potential treatment target in RA.
In immune cells such as monocytes and macrophages, the chaperone protein HSC70 regulates the immune response by provoking production of the cytokines IL-6, IL-1β and TNF-α. 29 Furthermore, HSC70 is also required for Histatin 3 to promote cell proliferation of human gingival fibroblasts. 30 A previous study detected the continuous enhanced expression of HSC70 in the synovial tissues of RA; 19 however, its exact function in RASFs remains unknown. In this study, a physiological interaction was observed between TXNDC5 and HSC70 protein in RASFs, and HSC70 closely mimicked the effects of TXNDC5 on the biological activity of RASFs, such as cell viability, invasion and cytokine production. In addition, we found that HSC70 could be maintained in the cytoplasmic compartment by TXNDC5, and HSC70, in turn, is responsible for the induction of TXNDC5 under inflammatory conditions, thus suggesting the establishment of a vicious cycle between TXNDC5 and HSC70 in the progression of RA.
Furthermore, we found that TXNDC5, similar to HSC70, 18 can regulate the activity of NF-κB signaling, indicating that TXNDC5 and HSC70 coordinate to sensitize RASFs to NF-κB signaling. Their effects on NF-κB signaling translated directly into functional consequences for RASF behavior, as demonstrated by the synergistic suppression of cell viability when silencing TXNDC5 and HSC70 simultaneously. Moreover, the modulation of TXNDC5 toward NF-κB signaling occurs in an HSC70-dependent manner, suggesting the importance of exploring the HSC70-mediated pathology in RA. The activity of NF-κB is primarily suppressed through cytoplasmic sequestration of NF-κB by the inhibitor of the κB (IκB) family of proteins. 31 IκBβ is degraded more rapidly than other IκBs in unstimulated cells, which subsequently increases the basal activity of NF-κB; inducible NF-kB activation remains relatively unaffected. 22, 23 As HSC70 is involved in the protein degradation of its targets in the absence of LPS stimulation, 16 we propose that HSC70 may regulate NF-κB signaling by accelerating the degradation of IκBβ in the absence of LPS, which was confirmed by our results. Moreover, in the presence of LPS, more IκBβ can translocate into the nucleus and facilitate the activity of p65, augmenting transcription of TNF-α. 22 We demonstrated that, following LPS stimulation, HSC70 siRNA could suppress IκBβ nuclear translocation and the level of IκBβ in this hypophosphorylated form. These data, therefore, suggest that depending on the inflammatory milieu, HSC70 plays a dual role in regulating IκBβ, thus facilitating the activity of NF-κB signaling. Of note, TXNDC5 showed the same effects on IκBβ as HSC70. More importantly, IκBβ mediates the regulation of TXNDC5/HSC70 on NF-κB signaling. Altogether, our study provides evidence of a functional link between TXNDC5, HSC70 and NF-κB signaling pathways in the regulation of proinflammatory mechanisms in RA.
In conclusion, our study sheds light on the proinflammatory role of TXNDC5 in the pathogenesis of RA, as summarized in Figure 6i . These TXNDC5-mediated effects support the presence of a positive loop linking HSC70 and NF-κB signaling in an immune response involving RASFs. A better understanding of TXNDC5/HSC70-mediated inflammatory pathways may lead to novel treatment strategies for RA.
